Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?

Movement Disorders

Volumn 31, Issue 7, 2016, Pages 937-946

  McDonald, Claire ^a,b   Newton, Julia L ^a,b   Burn, David J ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

3 iodobenzylguanidine; autonomic dysfunction; cognitive impairment; orthostatic hypotension; Parkinson's disease

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ATOMOXETINE; CHOLINESTERASE INHIBITOR; DROXIDOPA; FLUDROCORTISONE; LEVODOPA; MIDODRINE; NORADRENALIN; PLACEBO; PYRIDOSTIGMINE; RIVASTIGMINE;

BLOOD PRESSURE; BRAIN PERFUSION; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DEMENTIA; DISEASE ASSOCIATION; DISEASES; EMBASE; FAINTNESS; HEART DENERVATION; HUMAN; LOCUS CERULEUS; MEDLINE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NORADRENALIN BLOOD LEVEL; NORADRENERGIC SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHOTOELECTRIC PLETHYSMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

EID: 84977473076     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26632     Document Type: Review

References (99)

1. de Lau LML, Breteler MMB. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5(6):525–535.
2. Goetz CG. The history of Parkinson's disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med 2011;1(1):a008862.
3. Duncan GW, Khoo TK, Yarnall AJ, et al. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord 2014;29(2):195–202.
4. Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 2013;80(3):276–281.
5. Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review update: treatments for the non-motor symptoms of Parkinson's disease. Mov Disord 2011;26(S3):S42–S80.
6. Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8(5):464–474.
7. Kehagia AA, Barker RA, Robbins TW. Cognitive impairment in Parkinson's disease: the dual syndrome hypothesis. Neurodegener Dis 2013;11(2):79–92.
8. Lim SY, Lang AE. The nonmotor symptoms of Parkinson's disease—an overview. Mov Disord 2010;25(suppl 1):S123–S130.
9. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20(2):190–199.
10. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 2006;16(1):46–54.
11. Palma JA, Carmona-Abellan MM, Barriobero N, et al. Is cardiac function impaired in premotor Parkinson's disease? A retrospective cohort study. Mov Disord 2013;28(5):591–596.
12. Postuma RB, Gagnon JF, Pelletier A, Montplaisir J. Prodromal autonomic symptoms and signs in Parkinson's disease and dementia with Lewy bodies. Mov Disord 2013;28(5):597–604.
13. Allcock LM, Kenny RA, Mosimann UP, et al. Orthostatic hypotension in Parkinson's disease: association with cognitive decline? Int J Geriatr Psychiatry 2006;21(8):778–783.
14. Idiaquez J, Benarroch EE, Rosales H, Milla P, Rios L. Autonomic and cognitive dysfunction in Parkinson's disease. Clin Auton Res 2007;17(2):93–98.
15. Peralta C, Stampfer-Kountchev M, Karner E, et al. Orthostatic hypotension and attention in Parkinson's disease with and without dementia. J Neural Transm 2007;114(5):585–588.
16. Hohler AD, Zuzuarregui JR, Katz DI, et al. Differences in motor and cognitive function in patients with Parkinson's disease with and without orthostatic hypotension. Int J Neurosci 2012;122(5):233–236.
17. Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24(2):197–211.
18. Carlsson A. Evidence for a role of dopamine in extrapyramidal functions. Acta Neuroveg 1964;26(4):484–493.
19. Freeman R, Wieling W, Axelrod F, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21(2):69–72.
20. Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63(5):584–589.
21. Matinolli M, Korpelainen JT, Korpelainen R, Sotaniemi KA, Myllylä VV. Orthostatic hypotension, balance and falls in Parkinson's disease. Mov Disord 2009;24(5):745–751.
22. Ha AD, Brown CH, York MK, Jankovic J. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord 2011;17(8):625–628.
23. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23(6):837–844.
24. Goldstein DS, Eldadah BA, Holmes C, et al. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 2005;46(6):1333–1339.
25. Velseboer DC, de Haan RJ, Wieling W, Goldstein DS, de Bie RM. Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis. Parkinsonism Relat Disord 2011;17(10):724–729.
26. Jamnadas-Khoda J, Koshy S, Mathias CJ, Muthane UB, Ragothaman M, Dodaballapur SK. Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory? Mov Disord 2009;24(12):1747–1751.
27. Cooke J, Carew S, Quinn C, et al. The prevalence and pathological correlates of orthostatic hypotension and its subtypes when measured using beat-to-beat technology in a sample of older adults living in the community. Age Ageing 2013;42(6):709–714.
28. Frith J, Newton JL, Parry SW. Measuring and defining orthostatic hypotension in the older person. Age Ageing 2014;43(2):168–170.
29. Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord 2015;30(5):639–645.
30. Oka H, Mochio S, Yoshioka M, Morita M, Inoue K. Evaluation of baroreflex sensitivity by the sequence method using blood pressure oscillations and R-R interval changes during deep respiration. Eur Neurol 2003;50(4):230–243.
31. Szili-Török T, Kálmán J, Paprika D, Dibó G, Rózsa Z, Rudas L. Depressed baroreflex sensitivity in patients with Alzheimer's and Parkinson's disease. Neurobiol Aging 2001;22(3):435–438.
32. Friedrich C, Rudiger H, Schmidt C, et al. Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Mov Disord 2010;25(3):315–324.
33. Groothuis JT, Esselink RAJ, Seeger JPH, Van Aalst MJH, Hopman MTE, Bloem BR. Lower vascular tone and larger plasma volume in Parkinson's disease with orthostatic hypotension. J Appl Physiol 2011;111(2):443–448.
34. Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord 2013;28(6):715–724.
35. Papapetropoulos S, Mash DC. Insular pathology in Parkinson's disease patients with orthostatic hypotension. Parkinsonism Rel Disord 2007;13(5):308–311.
36. Matsui H, Udaka F, Miyoshi T, et al. Three-dimensional stereotactic surface projection study of orthostatic hypotension and brain perfusion image in Parkinson's disease. Acta Neurol Scand 2005;112(1):36–41.
37. Sakakibara R, Tateno F, Kishi M, Tsuyusaki Y, Terada H, Inaoka T. MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review. Parkinsonism Relat Disord 2014;20(3):267–273.
38. Leite MA, Nascimento OJ, Pereira JS, et al. Cardiac 123I-MIBG uptake in de novo Brazilian patients with Parkinson's disease without clinically defined dysautonomia. Arq Neuropsiquiatr 2014;72(6):430–434.
39. Chiaravalloti A, Stefani A, Tavolozza M, et al. Different patterns of cardiac sympathetic denervation in tremor-type compared to akinetic-rigid-type Parkinson's disease: molecular imaging with 123I-MIBG. Mol Med Rep;6(6):1337–1342.
40. Oka H, Toyoda C, Yogo M, Mochio S. Reduced cardiac 123I-MIBG uptake reflects cardiac sympathetic dysfunction in de novo Parkinson's disease. J Neural Transm 2011;118(9):1323–1327.
41. Matsui H, Nishinaka K, Oda M, Komatsu K, Kubori T, Udaka F. Does cardiac metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease correlate with major autonomic symptoms? Parkinsonism Relat Disord 2006;12(5):284–288.
42. Saiki S, Hirose G, Sakai K, et al. Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 2004;220(1-2):105–111.
43. Kish SJ, Shannak KS, Rajput AH, Gilbert JJ, Hornykiewicz O. Cerebellar norepinephrine in patients with Parkinson's disease and control subjects. Arch Neurol 1984;41(6):612–614.
44. Orimo S, Uchihara T, Nakamura A, et al. Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 2008;131(3):642–650.
45. Orimo S, Ozawa E, Oka T, et al. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 2001;57(6):1140–1141.
46. Mitsui J, Saito Y, Momose T, et al. Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci 2006;243(1-2):101–104.
47. Lenska-Mieciek M, Derecka-Charzynska I, Fiszer U, Krolicki L, Kulakowski P. Syncope and autonomic cardiovascular dysfunction in Parkinson disease. Neurol Neurochir Pol 2011;45(4):335–341.
48. Guidez D, Behnke S, Halmer R, et al. Is reduced myocardial sympathetic innervation associated with clinical symptoms of autonomic impairment in idiopathic Parkinson's disease? J Neurol 2014;261(1):45–51.
49. Haensch CA, Lerch H, Jorg J, Isenmann S. Cardiac denervation occurs independent of orthostatic hypotension and impaired heart rate variability in Parkinson's disease. Parkinsonism Relat Disord 2009;15(2):134–137.
50. Shibata M, Morita Y, Shimizu T, Takahashi K, Suzuki N. Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci 2009;276(1-2):79–83.
51. Berganzo K, Tijero B, Somme JH, et al. SCOPA-AUT scale in different parkinsonisms and its correlation with (123) I-MIBG cardiac scintigraphy. Parkinsonism Relat Disord 2012;18(1):45–48.
52. Barbic F, Perego F, Canesi M, et al. Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension. Hypertension 2007;49(1):120–126.
53. Senard JM, Valet P, Durrieu G, et al. Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. Euro J Clin Invest 1990;20(6):613–619.
54. Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci 2011;310(1-2):123–128.
55. Nakamura T, Hirayama M, Hara T, et al. Role of cardiac sympathetic nerves in preventing orthostatic hypotension in Parkinson's disease. Parkinsonism Relat Disord 2014;20(4):409–414.
56. Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study. Neurology 2014;82(4):308–316.
57. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease. Lancet Neurol 2010;9(12):1200–1213.
58. Robbins TW, Cools R. Cognitive deficits in Parkinson's disease: a cognitive neuroscience perspective. Mov Disord 2014;29(5):597–607.
59. Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J, Weintraub D. Cognitive impairment in nondemented Parkinson's disease. Mov Disord 2011;26(14):2483–2495.
60. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27(3):349–356.
61. Jellinger KA, Attems J. Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008;115(4):427–436.
62. Kövari E, Gold G, Herrmann F, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol 2003;106(1):83–88.
63. Sara SJ. The locus coeruleus and noradrenergic modulation of cognition. Nature reviews Neuroscience 2009;10(3):211–223.
64. Del Tredici K, Braak H. Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. Neurol Neurosurg Psychiatry 2013;84(7):774–783.
65. Espay AJ, LeWitt PA, Kaufmann H. Norepinephrine deficiency in Parkinson's disease: The case for noradrenergic enhancement. Movement Disorders 2014;29(14):1710–1719.
66. Pifl C, Kish SJ, Hornykiewicz O. Thalamic noradrenaline in Parkinson's disease: deficits suggest role in motor and non-motor symptoms. Mov Disord 2012;27(13):1618–1624.
67. Kitayama M, Wada-Isoe K, Irizawa Y, Nakashima K. Association of visual hallucinations with reduction of MIBG cardiac uptake in Parkinson's disease. J Neurol Sci 2008;264(1-2):22–26.
68. Kim J-S, Shim Y-S, Song I-U, et al. Cardiac sympathetic denervation and its association with cognitive deficits in Parkinson's disease. Parkinsonism Relat Disord 2009;15(9):706–708.
69. Matsubayashi K, Okumiya K, Wada T, et al. Postural dysregulation in systolic blood pressure is associated with worsened scoring on neurobehavioral function tests and leukoaraiosis in the older elderly living in a community. Stroke 1997;28(11):2169–2173.
70. Longstreth WT Jr, Manolio TA, Arnold A, et al. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996;27(8):1274–1282.
71. Gottesman RF, Catellier DJ, Coker LH, et al. 136th Annual Meeting Tuesday, September 27, 2011 Derek Denny-Brown New Member Symposium Abstracts. Ann Neurol 2011;70(S15):S1–S3.
72. Au R, Massaro JM, Wolf PA, et al. Association of white matter hyperintensity volume with decreased cognitive functioning: The Framingham Heart Study. Arch Neurol 2006;63(2):246–250.
73. de Groot JC, de Leeuw FE, Oudkerk M, et al. Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 2000;47(2):145–151.
74. Geerlings MI, Appelman AP, Vincken KL, Mali WP, van der Graaf Y. Association of white matter lesions and lacunar infarcts with executive functioning: the SMART-MR study. Am J Epidemiol 2009;170(9):1147–1155.
75. Longstreth WT Jr, Arnold AM, Beauchamp NJ Jr, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005;36(1):56–61.
76. Schmidt R, Ropele S, Enzinger C, et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian stroke prevention study. Ann Neurol 2005;58(4):610–616.
77. Van Den Heuvel DMJ, Ten Dam VH, De Craen AJM, et al. Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population. J Neurol Neurosurg Psychiatry 2006;77(2):149–153.
78. Erten-Lyons D, Woltjer R, Kaye J, et al. Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology 2013;81(11):977–983.
79. Holland CM, Smith EE, Csapo I, et al. Spatial distribution of white-matter hyperintensities in Alzheimer disease, cerebral amyloid angiopathy, and healthy aging. Stroke 2008;39(4):1127–1133.
80. Duering M, Csanadi E, Gesierich B, et al. Incident lacunes preferentially localize to the edge of white matter hyperintensities: insights into the pathophysiology of cerebral small vessel disease. Brain 2013;136(Pt 9):2717–2726.
81. Gouw AA, Seewann A, van der Flier WM, et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82(2):126–135.
82. O'Sullivan M. Leukoaraiosis. Pract Neurol 2008;8(1):26–38.
83. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke 1997;28(3):652–659.
84. Bowler JV. Editorial comment—the progression of leukoaraiosis. Stroke 2003;34(8):1916–1917.
85. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010;120(3):287–296.
86. Kim JS, Oh YS, Lee KS, Kim YI, Yang DW, Goldstein DS. Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology 2012;79(13):1323–1331.
87. Pilleri M, Facchini S, Gasparoli E, et al. Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease. J Neurol 2013;260(1):253–259.
88. Oh Y-S, Kim J-S, Lee K-S. Orthostatic and supine blood pressures are associated with white matter hyperintensities in Parkinson disease. J Mov Disord 2013;6(2):23–27.
89. Goldstein DS, Pechnik S, Holmes C, Eldadah B, Sharabi Y. Association between supine hypertension and orthostatic hypotension in autonomic failure. Hypertension 2003;42(2):136–142.
90. Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci 2011;310(1-2):123–128.
91. Phillips AA, Warburton DER, Ainslie PN, Krassioukov AV. Regional neurovascular coupling and cognitive performance in those with low blood pressure secondary to high-level spinal cord injury: improved by alpha-1 agonist midodrine hydrochloride. J Cereb Blood Flow Metab 2014;34(5):794–801.
92. Kalinin S, Polak PE, Lin SX, Sakharkar AJ, Pandey SC, Feinstein DL. The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease. Neurobiol Aging 2012;33(8):1651–1663.
93. Harada H, Noto T, Tsuji M, Taga C, Hashimoto H, Nakajima T. Effects of L-threo- and erythro-3,4-dihydroxyphenylserine on learning performance and concentrations of brain noradrenaline and its metabolites in rats. Pharmacol Biochem Behav 1992;43(1):215–221.
94. Kehagia AA, Housden CR, Regenthal R, et al. Targeting impulsivity in Parkinson's disease using atomoxetine. Brain 2014;137(Pt 7):1986–1997.
95. Marsh L, Biglan K, Gerstenhaber M, Williams JR. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009;24(2):277–282.
96. Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010;75(5):448–455.
97. Ramirez CE, Okamoto LE, Arnold AC, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2014;64(6):1235–1240.
98. Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev 2006(1):CD004747.
99. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008;7(5):451–458.